Frederick Stoddard, MD
Psychiatry · Narberth, PANPI 1447384193
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,698 of the $71,902 with a category attached, or 80.2%. Johnson & Johnson accounts for 60.3% of it on its own, with 29 other manufacturers making up the rest. 2025 is the largest year on record at $29,730, more than ten times the $525 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $196.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$43K
- Axsome Therapeutics, Inc.$12K
- AbbVie$10K
- Brainsway USA Inc$2K
- Ironshore Pharmaceuticals Inc.$621
- Otsuka America Pharmaceutical, Inc.$460
- plus $3K from 24 others
Across 7 payments — averaging $3773.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$20K
- Brainsway USA Inc$6K
What the payments were for
- Speaking & faculty fees$57,69880%
- Travel & lodging$3,7255%
- Food & beverage$10,48015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 70 | $43,389 |
| Axsome Therapeutics, Inc. | 28 | $12,229 |
| AbbVie(2 entities) | 76 | $10,010 |
| Brainsway USA Inc | 2 | $1,982 |
| Ironshore Pharmaceuticals Inc. | 30 | $621 |
| Otsuka America Pharmaceutical, Inc. | 23 | $460 |
| Jazz Pharmaceuticals Inc. | 8 | $393 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $324 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $280 |
| Harmony Biosciences LLC | 9 | $274 |
| Neurocrine Biosciences, Inc. | 10 | $222 |
| Lundbeck LLC | 11 | $221 |
| Indivior Inc. | 6 | $194 |
| Alkermes, Inc. | 7 | $159 |
| Bausch Health US, LLC | 8 | $156 |
| Teva Pharmaceuticals USA, Inc. | 8 | $143 |
| Eisai Inc. | 6 | $128 |
| Collegium Pharmaceutical, Inc. | 6 | $107 |
| Braeburn Inc. | 5 | $100 |
| Vanda Pharmaceuticals Inc. | 4 | $93 |
| Supernus Pharmaceuticals, Inc. | 4 | $70 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Corium, LLC | 2 | $48 |
| Almatica Pharma LLC | 2 | $48 |
| Tris Pharma Inc | 3 | $46 |
| Sage Therapeutics, LLC | 2 | $41 |
| Merck | 2 | $36 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$42,097
- Auvelity$11,491
- VRAYLAR$9,239
- Brainsway Deep TMS System$1,853
- XYWAV$148
- Deep TMS System$129
- SUNOSI$119
- Wakix$107
How this compares
$71,902 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 21 | $85,416 |
| AplenzinBupropion Hbr | 12 | $66,513 |
| VraylarCariprazine Hcl | 19 | $23,274 |
| Vilazodone Hcl | 12 | $1,719 |
| Modafinil | 21 | $777 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $263 |
| Clonazepam | 16 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $43,389 | $85,41621 claims |
| Bausch Health US, LLCAplenzin | $156 | $66,51312 claims |
| AbbVieVraylar | $10,010 | $23,27419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Narberth
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.